tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Clinical Trials'

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

Written by Ι Stock Market Media — February 4, 2019

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...

Read More →
0

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Written by Ι Stock Market Media — May 18, 2017

Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...

Read More →
0

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

Written by Ι Stock Market Media Group Staff — April 14, 2015

NEW YORK, NY – Plandaí Biotechnology (OTCQB: PLPL) and its operations at the Senteeko tea estate in South Africa are the subject of a newly released video. Stock Market Media Group, a content development investment relations firm, spent a week in South Africa with a camera crew from Bay Colony Media documenting the company’s story, and announced today that the documentary is now available.  

Click Here to View ...

Read More →
0

Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment with License for Insulin-Producing Cells

Written by Ι Stock Market Media Group Staff — October 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology.  It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.

Now, almost ...

Read More →
0

Nuvilex Appoints Dr. Matthias Lohr as Chairman of Scientific Advisory Board

SILVER SPRING, MD., Oct. 6, 2014 — Nuvilex, Inc.Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of Nuvilex’s newly formed Scientific Advisory Board.

Dr. Lohr has been a full professor of gastroenterology and hepatology at the famed Karolinska Institute in Stockholm, Sweden, since 2007. He has served as Professor of Molecular Gastroenterology at the University ...

Read More →
0

Nuvilex and TD2 Begin Preparations for US-Based Studies on Symptoms Associated With Pancreatic Cancer

SILVER SPRING, Md., May 21, 2014 — Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that, together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer.

TD2 will study the effectiveness of Nuvilex’s ...

Read More →
0
Page 1 of 6 12345...»
ContactUs.com